Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

Aliment Pharmacol Ther 2012; 35: 15–36 Summary Background Thiopurines represent an
effective and widely prescribed therapy in inflammatory bowel disease (IBD). Concerns …

Inflammatory bowel disease is characterized by significant interindividual heterogeneity.
With a wider selection of pharmacologic and nonpharmacologic interventions available and …

Azathioprine is a thiopurine immunosuppressant drug that occupies an important place in
the management of many autoimmune and inflammatory skin diseases. Its parent drug 6 …

Background Thiopurine‐induced leukopenia is the most common dangerous adverse event
in Asians. NUDT 15 R139C was recently proposed to be a promising biomarker for …

Background Azathioprine and mercaptopurine have a pivotal role in the treatment of
inflammatory bowel disease (IBD). However, because of their complex metabolism and …

Aliment Pharmacol Ther 31, 640–647 Summary Background The thiopurine drugs,
azathioprine and mercaptopurine (MP), are established treatments for IBD. However …

Crohn's disease and ulcerative colitis affect an increasing number of patients. A variety of
medical options exist for the treatment of these diseases including immune suppressants …

Thiopurines are often the mainstay of treatment for many patients with inflammatory bowel
disease. As such, a general understanding of the evidence behind their use and of their …

Introduction: Crohn's disease and ulcerative colitis affect an increasing number of patients,
and utilization of immune suppressant and biologic therapies is also increasing. These …